Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/IIa Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of DC05F01 in Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

NCT06873555 is registered in ClinicalTrials.gov with Heronova Pharmaceuticals as lead sponsor.

NCT NCT06873555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/IIa Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of DC05F01 in Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Lead sponsor
Heronova Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 11, 2024
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, small cell lung cancer, solid tumors